Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1856 • 2013 ACR/ARHP Annual Meeting
Potentiating Effects Of IL-17A, IL-17AF, IL-17F In Combination With TNF But Not With IL-1beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Christine Huppertz¹, Marija Curcic Djuric¹, Robert Hennze¹, Friedrich Raulf¹, Frank Kolbinger¹, Anis Mir¹ and David Lee², ¹Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The pro-inflammatory cytokine interleukin-17A (IL-17A) activates fibroblast-like synoviocytes (FLS) and other mesenchymal cells via the IL-17RA/RC receptor. FLS are a major source of inflammatory…
Abstract Number: 934 • 2013 ACR/ARHP Annual Meeting
Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^1,2, Toshihisa Maeda¹, Shinya Hayashi³ and Masahiro Kurosaka³, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT,…
Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
MC Genovese¹, Joel M. Kremer², Ronald F. van Vollenhoven³, Rieke Alten⁴, Juan José Scali⁵, Ariella Kelman⁶, Lucy Rowell⁷ and Laura Pitts⁷, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany Medical College, Albany, NY, ³Karolinska Institute, Stockholm, Sweden, ⁴Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁵Durand University Hospital, Buenos Aires, Argentina, ⁶Genentech, South San Francisco, CA, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
Abstract Number: 2354 • 2013 ACR/ARHP Annual Meeting
Drug Survival Rates Of Anti-Tumor Necrosis Factor Therapies In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Dong-Jin Park¹, Kyung-Eun Lee¹, Ji-Hyoun Kang², Jeong-Won Lee², Tae-Jong Kim³, Yong-Wook Park¹ and Shin-Seok Lee⁴, ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Chonnam National University Medical School, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: We investigated the compliance of Korean patients using anti-tumor necrosis factor (TNF) agents to treat rheumatoid arthritis (RA) and anklyosing spondylitis (AS), and identified…
Abstract Number: 1792 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis
Daniel Dairaghi¹, Penglie Zhang², Manmohan Leleti², Robert Berahovich³, Karen Ebsworth³, Linda Ertl³, Shichang Miao⁴, Zhenhua Miao³, Lisa Seitz³, Joanne Tan³, Matthew Walters³, Yu Wang³, Jay Powers⁵, Thomas J. Schall⁶ and Juan C. Jaen⁷, ¹Biology, ChemoCentryx, Inc., Mountain View, CA, ²Chemistry, ChemoCentryx, Mountain View, CA, ³Biology, ChemoCentryx, Mountain View, CA, ⁴Pharmacokinetics, ChemoCentryx, Inc., Mountain View, CA, ⁵ChemoCentryx, Mountain View, CA, ⁶ChemoCentryx, Inc., Mountain View, CA, ⁷Discovery and Preclinical Development, ChemoCentryx, Inc., Mountain View, CA
Background/Purpose: Chemokines are key regulators of leukocyte activation and recruitment to sites of inflammation. Of particular relevance in rheumatoid arthritis (RA), the chemokine receptors CCR1…
Abstract Number: 943 • 2013 ACR/ARHP Annual Meeting
Synergism Between Granulocyte-Macrophage Colony Stimulating Factor and Interleukin-17 Causes Joint Damage Via The Production Of Interleukin-23, Receptor Activator Of NF-κB Ligand and S100A8
Annemarie E.M. Van Nieuwenhuijze¹, Fons A.J. Van de Loo², Birgitte Walgreen³, Miranda B. Bennink⁴, Monique M. Helsen³, Liduine Van den Bersselaar¹, Ian P. Wicks^5,6, Wim B. Van den Berg⁷ and Marije I. Koenders⁷, ¹Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia, ⁶Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ⁷Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…
Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴, Dan Nemes⁵, Rodica Chirieac⁶, Paulina Ciurea⁷, Maria Suta⁸, Andra Balanescu⁹, Eugenia Mociran¹⁰ and Elena Rezus¹¹, ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁶C.M.I. Rodica Chirieac, Iasi, Romania, ⁷Emergency County Hospital, Craiova, Romania, ⁸Emergency County Hospital, Constanta, Romania, ⁹Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ¹⁰Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…
Abstract Number: 2364 • 2013 ACR/ARHP Annual Meeting
Baseline Procalcitonin Levels Are Predictive Marker Of Remission In Biologic naïve Patients With Rheumatoid Arthritis Treated With Tocilizumab: Result From 24 Weeks Of Follow-Up
Soichiro Tsuji¹, Akiko Yura², Michihito Katayama¹, Satoru Teshigawara¹, Maiko Yoshimura¹, Eriko Tanaka¹, Yoshinori Harada², Yoshinori Katada², Masato Matsushita³, Shiro Ohshima⁴, Jun Hashimoto¹ and Yukihiko Saeki⁴, ¹Dept of Rheumatology, Rheumatology,Osaka-Minami Medical Center, Kawachinagano City, Japan, ²Dept of Allergology, Allergology,Osaka-Minami Medical Center, Kawachinagano City, Japan, ³Rheumatology, Rheumatology,Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Dept of Clinical Research, Clinical Research,Osaka-Minami Medical Center, Kawachinagano City, Japan
Background/Purpose: , :Procalcitonin(PCT) is a useful marker of infection. PCT-mRNA increases expression from peripheral blood mononuclear cells by stimulation of a pro inflammatory cytokine, IL-6…
Abstract Number: 1794 • 2013 ACR/ARHP Annual Meeting
The Jak Inihibitor Tofacitinib Suppresses Synovial Jak-Stat Signalling In Rheumatoid Arthritis
D. L Boyle¹, N. Wei², A. K. Singhal³, D. R. Mandel⁴, P Mease⁵, A. Kavanaugh⁶, R. Shurmur⁷, J. Hodge⁸, Z. Luo⁹, S. Krishnaswami¹⁰, D. Gruben⁹, S. H. Zwillich⁹, K. Soma⁹, J. D. Bradley⁹ and G. S. Firestein¹¹, ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²Arthritis Treatment Center, Frederick, MD, ³Southwest Rheumatology Research LLC, Mesquite, TX, ⁴Office of David R Mandel MD, Inc., Mayfield Village, OH, ⁵Seattle Rheumatology Associates, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA, ⁷Associated Internal Medicine Specialists, Battle Creek, MI, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Groton, CT, ¹⁰Clinical Pharmacology, Pfizer Inc, Groton, CT, ¹¹Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The specific JAK-STAT (signal transducer and activator of…
Abstract Number: 948 • 2013 ACR/ARHP Annual Meeting
Dual Neutralization Of TNF and IL-17 Provides Greater Efficacy In Collagen Induced Arthritis Through Regulation Of a Gene Transcription Program That Includes CXCL1 and CXCL5
Carolyn Cuff¹, Chung-Ming Hsieh², Suzanne Mathieu³, Anwar Murtaza⁴, Margaret Hugunin³, Shaughn Bryant³, Robert O'brien³, Lisa Olson⁵ and Jeffrey Voss³, ¹Immunology, AbbVie, Inc, Worcester, MA, ²Biologics, AbbVie Pharmaceuticals, Worcester, MA, ³Immunology, AbbVie Pharmaceuticals, Worcester, MA, ⁴Broad Institute, Cambridge, MA, ⁵AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Dual neutralization of TNF and IL-17 is hypothesized to provide greater efficacy in rheumatoid arthritis (RA) and inflammatory diseases compared to either monotherapy as…
Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Thomas Doerner¹, Hans Peter Tony², Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kaestner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, S. Wagner⁸, Marvin A. Peters⁹ and Christof Iking-Konert¹⁰, ¹Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, ²Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany, ⁴Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, ⁵Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, ⁶Centre for Inflammatory Joint Diseases, Munich, Germany, ⁷Rheumapraxis, Aachen, Germany, ⁸Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
Abstract Number: 2370 • 2013 ACR/ARHP Annual Meeting
The Effectiveness Of Biological Agents Concomitant With Tacrolimus In Rheumatoid Arthritis
Kenya Terabe¹, Toshihisa Kojima², Nobunori Takahashi¹, Koji Funahashi³, Atsushi Kaneko⁴, Daihei Kida⁵, Yuichiro Yabe⁶, Yuji Hirano⁷, Masatoshi Hayashi⁸ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁵Department of Rheumatology and Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁶Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan, ⁷Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁸Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan
Background/Purpose:In Japan, oral tacrolimus (TAC) was approved for the treatment of RA in 2005 and the improvement of symptoms thorough the use concomitant with disease…
Abstract Number: 1728 • 2013 ACR/ARHP Annual Meeting
Amelioration Of Collagen-Induced Arthritis By Modulation Of Inhibitory Apoptosis Stimulating Protein Of p53 To Activate Transcription Factor p73
Chrong-Reen Wang¹, Shih-Yao Chen², Ai-Li Shiau³, Yuan-Tsung Li⁴, Chia-Tse Weng⁵, I-Ming Jou⁶, Ming-Fei Liu⁷ and Chao-Liang Wu², ¹Section of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ²Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, ³Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ⁴Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ⁵Internal Medicine, National Cheng Kung University Medical College, Tainan, Taiwan, ⁶Orthopedics, National Cheng Kung University Medical College, Tainan, Taiwan, ⁷Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Background/Purpose: Our previous studies have demonstrated p53 mutations competent for the inactivation of wild type p53 in synovial fibroblasts (SF) from either rheumatoid arthritis patients…
Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting
Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study
James Dale¹, Anne Stirling², Iain B. McInnes¹ and Duncan Porter³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Gartnavel General Hospital, Glasgow, United Kingdom, ³Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom
Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…
Abstract Number: 439 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
E. B. Lee¹, J. R. Curtis², R. Riese³, C. A. Connell³, R. Chew³, M.G. Boy³, E. Maller⁴, C. Su⁴ and L. Wang³, ¹Seoul National University, Seoul, South Korea, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This analysis aimed to describe and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].